Kromek lays out long-term ambitions after Siemens breakthrough

Kromek Group PLC's Capital Markets Day highlights growth opportunities in Advanced Imaging and CBRN detection, underpinned by its CZT technology. The Siemens Healthineers deal, involving a $25 million payment and manufacturing transfer, has strengthened Kromek's balance sheet and position in medical imaging. Management aims for £60 million in medium-term revenues and a 30% EBITDA margin, with Cavendish maintaining its 26p price target and noting the event provides a framework for investors to evaluate the company's progress.

Analysis

Kromek Group PLC is leveraging its Capital Markets Day to articulate significant long-term ambitions, primarily focusing on its two core growth engines: Advanced Imaging and CBRN (chemical, biological, radiological, and nuclear) detection, both underpinned by its proprietary cadmium zinc telluride (CZT) technology. A pivotal development validating its strategy is the January agreement with Siemens Healthineers, which included a substantial $25 million payment and a transfer of manufacturing capabilities, thereby materially strengthening Kromek's balance sheet and affirming its leadership in next-generation medical imaging. The company is strategically positioned in Advanced Imaging to capitalize on the transition towards CZT detectors in both SPECT and, notably, CT scans, with the latter market segment projected for sharp growth over the next five years. Concurrently, its CBRN division is poised for expansion driven by anticipated government stockpiling initiatives, increasing demand from EU and NATO, and new security contracts in the UK and US. Management has set ambitious medium-term financial targets, aiming for £60 million in revenues and a 30% EBITDA margin. While broker Cavendish has maintained its 26p price target and current forecasts, it notes that these articulated goals provide investors with a clear framework to assess the company's future performance. Despite a significant 31% year-to-date share price increase to 6.57p, the current price remains substantially below Cavendish's target, suggesting perceived upside based on successful execution of these plans.

Key Decisions for Investors

• Consider the significant valuation gap between the current share price of 6.57p and Cavendish's 26p target, alongside the company's ambitious £60 million revenue and 30% EBITDA margin goals, as indicative of substantial potential upside if strategic execution is successful.
• Monitor Kromek's ability to secure new contracts in its CBRN division and demonstrate market penetration in the Advanced Imaging sector, particularly regarding the adoption of CZT detectors in CT scans, as key milestones for achieving its medium-term financial targets.
• Evaluate the ongoing impact of the Siemens Healthineers partnership on accelerating growth and validating Kromek's technology, using management's articulated framework from the Capital Markets Day to track progress against their long-term ambitions, especially since the shares have already appreciated 31% year-to-date.